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Abstract
Background—Hyperinsulinemia resulting from obesity and insulin resistance is associated with
increased risk of many cancers, but the biology underlying this risk is unclear. We hypothesized
that increased mRNA levels of the insulin-like growth factor 1 receptor (IGF1R) versus the insulin
receptor (IR) or elevated ratio of IR-A:IR-B isoforms in normal rectal mucosa would
predictadenoma risk, particularly in individuals with high body mass index (BMI) or plasma
insulin.
Methods—Biopsies from normal rectal mucosa were obtained from consenting patients
undergoing routine colonoscopy at UNC Hospitals. Subjects with colorectal adenomas were
classified as cases (n = 100) and were matched to adenoma-free controls (n = 98) based on age,
sex and BMI. IGF1R and IR mRNA levels were assessed by qRT-PCR, and IR-A:IR-B mRNA
ratios by standard PCR. Plasma insulin and crypt apoptosis were measured by ELISA and
TUNEL, respectively. Logistic regression models examined relationships between receptor
mRNAs, BMI, plasma insulin and adenoma risk.
Results—Unexpectedly, cases were significantly more likely to have lower IGF1R mRNA levels
than controls. No overall differences in total IR mRNA or IR-A:IR-B ratios were observed
between cases and controls. Interestingly, in patients with high plasma insulin, increased IR-A:IR-
B ratio was associated with increased likelihood of having adenomas.
Conclusions—Our work shows novel findings that reduced IGF1R mRNA and, during high
plasma insulin, increased IR-A:IR-B ratios in normal rectal mucosa are associated with colorectal
adenoma risk.
Impact—Our work provides evidence supporting a link between IGF1R and IR isoform
expression levels and colorectal adenoma risk.
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Introduction
Despite increased colonoscopy-based screening and improved treatment strategies (1),
colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the
United States (2). Obesity, insulin resistance and type 2 diabetes are considered risk factors
for CRC (3–5). Previous work by our group has linked elevated plasma insulin and low
apoptosis in normal rectal mucosa to increased adenoma risk (6–8). Elevated plasma insulin
(hyperinsulinemia) can increase levels of free insulin-like growth factor 1 (IGF1) in the
circulation by inhibiting the production of IGF binding protein 1 (IGFBP1) (9, 10). In recent
years, there has been increasing interest in targeting the insulin/IGF pathway for cancer
treatment, as a large body of evidence links insulin/IGF1-mediated activation of insulin
receptor (IR) or IGF1 receptor (IGF1R) to cancer of multiple organs (11–16). Furthermore, a
number of studies have shown that IGF1R confers resistance to radiation therapy and
chemotherapy (17, 18), and clinical evidence links IGF1R over-expression to colorectal
tumor formation and progression (19, 20). Although IGF1R inhibitors showed a potential to
reduce tumor growth (21, 22), recent reports suggested that IR may permit tumors to resist
IGF1R inhibition, which led to the development of dual IGF1R/IR inhibitors (23–26).
Considerable evidence has highlighted the potential significance of different IR isoforms in
growth and cancer (14, 27, 28). The IR gene yields two distinct IR isoforms due to alternate
pre-mRNA splicing. IR-B is encoded by an mRNA that includes exon 11 and is the primary
mediator of the metabolic actions of insulin (12, 29). IR-A is encoded by an mRNA that
lacks exon 11, plays a role in fetal growth and may mediate proliferative or anti-apoptotic
actions of insulin or the IGFs (27, 28). Evidence that IR-A may be the predominant IR
isoform in tumors or tumor cells (12, 14, 27, 28, 30), including colon tumors (31, 32), has
increased attention on this isoform as a possible mediator of cancer development or growth.
However, the finding that IR-A knockdown increased viability of a colon cancer cell line via
enhanced IGF1R activation (32) indicates that when IGF1R signaling is intact, IR may limit
IGF1R signaling. Thus, the roles of IGF1R vs. IR in promoting colorectal tumorigenesis are
not defined.
Little attention has been given to IGF1R and IR mRNA expression patterns during pre-
neoplastic stages of malignancy, including whether IGF1R or IR levels in normal colorectal
tissue differ between patients with adenomas and patients without adenomas. We
hypothesized that elevated mRNA levels of IGF1R vs. IR or elevated IR-A:IR-B ratio in
normal mucosa are associated with increased colorectal adenoma risk, elevated plasma
insulin, and overweight/obese body mass index (BMI). To address this hypothesis, biopsies
from normal rectal mucosa were obtained from adenoma or adenoma-free patients
undergoing routine colonoscopy. Levels of mRNAs encoding IGF1R, IR and IR isoforms
were quantified and the relationship between their expression, adenoma status, BMI and
plasma insulin was evaluated.
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Participants were randomly selected from eligible subjects enrolled in the Diet and Health
Study V (DHS V) who provided written informed consent and underwent routine
colonoscopy at the University of North Carolina Hospitals, Chapel Hill, NC. The DHS V
cohort has been described in previous studies (33–36). For the present study, a subset of 100
cases and 98 controls were selected so that the two groups were matched based on age,
gender and BMI. Patients were excluded from the study if they had cancer, colitis, 100 or
more polyps (polyposis), prior resection of the colon, or history of colorectal adenomas.
Colonoscopy was performed by certified gastroenterologists and all polyps were removed
for pathological examination and were not available for research purposes. Adenomas were
confirmed and defined according to standard pathological criteria. Subjects with one or more
adenomas were classified as “cases”and those without adenomas as “controls”. The study
was approved by the School of Medicine Institutional Review Board at the University of
North Carolina, Chapel Hill.
Data collection
Methods for data collection were previously described (33–36). Briefly, participants fasted
overnight and body weight, height, and waist and hip circumference were measured at the
time of colonoscopy. Within 3 months after colonoscopy, patients were interviewed by
telephone to provide information about their lifestyle, diet and demographics. BMI between
18.5–24.9 kg/m2 (lean) was defined as “normal” and BMI equal to or higher than 25 kg/m2
(overweight/obese) was defined as “Ovt/Ob”.
Biological specimens and laboratory assays
Prior to the endoscopic procedure, normal mucosal pinch biopsies were obtained 8–12 cm
from the anal verge using standard disposable, fenestrated forceps. Sampling site was the
same in all patients. Two biopsies were pooled for RNA extraction and immediately flash
frozen in liquid nitrogen and later transferred to −80°C. Another biopsy was fixed in 10%
buffered formalin for histology and evaluation of apoptosis. Blood was collected via an
intravenous catheter prior to administration of medication. Plasma was separated and insulin
levels assayed for 95 controls and 79 cases by ELISA (Diagnostic Systems Laboratory,
Webster, TX) as previously described (8). Plasma insulin levels below or above the median
were defined as “low” or “high”, respectively.
Assays for apoptosis
Formalin fixed rectal biopsies were embedded in paraffin. Apoptosis was scored by terminal
deoxynucleotidyltransferased UTP nick end labeling (TUNEL) using ApopTag Peroxidase
In Situ Apoptosis Detection Kit (Millipore, Billerica, MA). This technology detects
apoptotic cells by incorporating digoxigenin-conjugated nucleotides to the 3’OH termini of
DNA fragments utilizing terminal deoxynucleotidyltransferase (TdT). Briefly, samples were
deparaffinized in 100%, 95% and 70% ethanol, digested in proteinase K and blocked in 2%
hydrogen peroxide. TdT reaction was performed for 1.5 hours at 37°C. Anti-digoxigenin
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conjugate was applied to the slides for 30 minutes, followed by a DAB (3, 3'-
Diaminobenzidine) reaction for 1 minute. Samples were counterstained with hemotoxylin
and dehydrated with 95% and 100% ethanol and xylene. Slides were cover slipped using
Eukitt mounting medium (Sigma-Aldrich, St. Louis, MO) and visualized with a bright-field
microscope. Open crypts with good orientation were selected for scoring. The mean number
of TdT-labeled apoptotic cells per crypt was calculated for each patient sample by
investigators blinded to adenoma status. Due to the low number of samples available for
apoptosis scoring (21 controls and 68 cases), it was only possible to compare apoptosis in
cases versus controls without further stratification.
RNA Extraction, Reverse Transcription (RT) and PCR
RNA was extracted from biopsies using RNeasy Kit (Qiaen, Valencia, CA) and reverse
transcribed with High Capacity cDNA Reverse Transcription Kit, including RNase inhibitor
(Applied Biosystems, Carlsbad, CA) according to manufacturer’s protocol. Quantitative
real-time polymerase chain reaction (qRT-PCR) used the 7500 Real-Time PCR System
(Applied Biosystems, Carlsbad, CA) to quantify IGF1R and IR mRNA levels.
Hydroxymethylbilane synthase (HMBS), which we have found to be invariant across rectal
biopsy mRNAs, was used as the housekeeping gene for normalization. The following
TaqMan primer/probes (Applied Biosystems, Carlsbad, CA) were used: Hs00951562_m1
(IGF1R), Hs00961550_m1 (IR), and Hs00609297_m1 (HMBS). Pooled cDNA from
colorectal cancer cell lines (Caco-2, SW480, Colo205) was run in all assays as a positive,
internal control to account for inter-run variability. Samples were run in duplicate and water
was run as a negative control. Reaction cycles consisted of initial denaturation at 95°C for 5
minutes, 45 cycles of 95°C denaturation for 15 seconds and 60°C annealing for 45 seconds.
Data were analyzed using the Applied Biosystems 7500 software v2.0.1 and expression
levels were calculated using the standard curve method. These values were then normalized
to HMBS and to the internal control.
IR isoforms A and B were assessed by traditional, semi-quantitative PCR using 150 ng of
cDNA template. Forward primer 5’-GAATGCTGCTCCTGTCCAAA -3’ and reverse
primer 5’- TCGTGGGCACGCTGGTCGAG -3’ (Integrated DNA Technologies, Coralville,
IA) were designed to flank exon 11, resulting in 250 bp (IR-B) and 214 bp (IR-A) amplified
fragments. PCR protocol was modified from Brierley et al. (32) and consisted of initial
denaturation at 92°C for 5 minutes followed by 40 cycles of 92°C denaturation for 30
seconds, 60°C annealing for 30 seconds and 72°C extension step for 30 seconds. Water and
the internal control cDNA mentioned above were included in every assay. PCR products
were run and visualized in a 2.5% agarose gel and band intensities were measured using
Image J software (National Institutes of Health). Ratios of IR-A to IR-B were calculated for
each patient sample and normalized to the internal control. All PCR assays were performed
by an investigator blinded to case-control and BMI status, and samples were randomly
organized by another investigator so that all the groups were represented in each assay run.
Statistical analysis
Means and standard errors were computed for continuous variables. Differences in
continuous or categorical variables between adenoma cases and adenoma-free controls were
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compared by Student’s t-test or Chi-square test, respectively. BMI was divided into
“normal” and“Ovt/Ob” (overweight/obese) and plasma insulin levels into “low” (below the
median) and “high” (above the median) subgroups as described above. For each receptor
mRNA, the levels in controls were used to generate quartiles, and the lowest quartile was
considered as reference. Logistic regression models were used to compute odds ratios (ORs)
and 95% confidence intervals (CIs) to examine the association between mRNA quartiles
(predictors) and adenoma status (response). We also calculated P-values for interactions
between mRNA variables and BMI/insulin subgroups in a model testing for an association
with case status. The relationship between plasma insulin and receptor mRNA levels was
evaluated by Spearman’s correlation coefficient. P-values less than 0.05 were considered
statistically significant. All analyses were performed using SAS Version 9.3 (SAS Institute,
Cary, NC).
Results
Patient samples in this study were selected so that cases and controls were matched on age,
sex and BMI. Subject characteristics are summarized in Table 1. Race was not associated
with control or case status, and no differences in WHR, reported calorie intake or reported
physical activity were observed between cases and controls. Consistent with previous
studies from our group (6, 7), adenoma cases showed lower apoptosis (p=0.008) and a trend
towards increased plasma insulin (p=0.055) relative to adenoma-free controls.
IGF1R and IR mRNA levels in normal rectal mucosa were quantified by qRT-PCR. IR-A
and IR-B mRNAs were assessed by standard PCR, where amplification of both isoforms by
identical primers allowed us to calculate the ratio of IR-A:IR-B amplicon in each patient
sample. We first compared mean mRNA levels between controls and cases overall and after
stratifying for BMI and plasma insulin (Table 2). Overall, cases had significantly lower
IGF1R mRNA levels (p=0.0003) than controls. This reduction in IGF1R mRNA was
statistically significant in both normal (p=0.02) and Ovt/Ob (p=0.01) BMI subgroups and in
subjects in the lower half of plasma insulin (p=0.007). Since cases had slightly higher
plasma insulin levels than controls, and elevated insulin can down-regulate IGF1R as a
consequence of increased free IGF1 in the circulation (37, 38), we asked if the lower IGF1R
mRNA observed in cases could be associated with higher plasma insulin. Therefore, we
examined IGF1R mRNA levels in controls versus cases after adjusting for plasma insulin.
This analysis showed that even after controlling for insulin, cases still had lower IGF1R than
controls (p=0.005). Total IR mRNA levels did not differ between cases and controls in any
subgroup categorized for BMI or plasma insulin. IR-A:IR-B ratio was 1.96 ± 0.04 in
controls and 1.96 ± 0.03 in cases, demonstrating approximately 2 fold higher IR-A mRNA
expression in human rectum compared with IR-B, but no significant difference in cases and
controls as a whole or when stratified for BMI (Table 2). Interestingly, among patients with
high plasma insulin, adenoma cases had small but significant increases in IR-A:IR-B ratios
relative to controls (p=0.006), which qualitatively reflected reduced IR-B mRNA (Figure 1).
To further evaluate the potential relationship between mRNA levels and colorectal adenoma
risk, we studied the association between quartiles of IGF1R, IR and IR-A:IR-B mRNA
expression and the odds of being a case, with the lowest quartile set as the reference (Table
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3). Subjects in the highest two quartiles for IGF1R mRNA were significantly less likely to
be cases. There were no significant associations between IR mRNA, IR-A:IR-B ratio and
case status. To explore the association between receptor mRNA expression and adenoma
risk in each subgroup, we used a logistic regression model to test for interactions between
mRNA levels and BMI or plasma insulin status (Table 4). We found no interactions between
BMI or plasma insulin and either IGF1R or IR mRNA levels. We did, however, observe a
significant interaction between plasma insulin and IR-A:IR-B ratio (p=0.005). With
increasing IR-A:IR-B mRNA ratios, patients with high plasma insulin were more likely to
have adenomas than were patients with low plasma insulin (Supplementary Fig. S1).
We next compared mRNA expression between subgroups in controls and cases separately.
We found that in the control group, subjects with high plasma insulin had reduced mean
IGF1R, IR and IR-A:IR-B mRNA levels (p=0.048, p=0.02, p=0.01, respectively) relative to
subjects with low plasma insulin. This association was not found in cases. Qualitative
evaluation of the IR isoforms suggested that the reduced IR-A:IR-B ratio observed in
controls with high insulin reflected higher IR-B (Figure 1). To further examine the possible
effect of elevated insulin on gene expression, we calculated the correlation coefficients
between plasma insulin and IGF1R, IR and IR-A:IR-B mRNA levels (Table 5). We indeed
found significant negative correlations between plasma insulin and all three mRNA
variables in controls, while in cases this relationship was significant only for IGF1R mRNA.
In fact, in cases there was a non-significant trend for a positive correlation between IR-A:IR-
B ratio and plasma insulin (p=0.06).
Discussion
This case-control study provides novel evidence that, compared to adenoma-free controls,
rectal mucosal biopsies of patients with adenomas are likely to have 1) significantly lower
levels of IGF1R mRNA, 2) unaltered IR mRNA, and 3) higher ratios of IR-A:IR-B isoforms
in those individuals with elevated plasma insulin. Consistent with our previous findings in
three different patient groups (6–8), the presence of adenomas was associated with reduced
apoptosis in normal appearing rectal mucosa and increased plasma insulin, although the
latter was borderline significant in this smaller study population.
Identifying molecular biomarkers that predict early pre-cancerous lesions could significantly
improve our understanding of factors that promote CRC risk, which could eventually
contribute to better CRC prevention or screening. This study aimed to establish whether
elevated mRNA expression of IGF1R, IR or relative expression of isoforms IR-A and IR-B
in normal rectal mucosa predicts adenomas and whether this is influenced by BMI or plasma
insulin levels. IGF1R signaling can be activated during elevated insulin and has been linked
to reduced apoptosis and cancer progression in a number of organs, including the intestine
(11, 13, 39). Thus, we hypothesized that patients with adenomas would have up-regulated
IGF1R mRNA expression in their normal rectal mucosa, particularly in those with high
plasma insulin. Unexpectedly, we found that cases had significantly lower IGF1R mRNA
levels than controls, and the odds of having colorectal adenomas diminished with increasing
IGF1R mRNA expression. We considered whether elevated insulin could be linked to the
reduced IGF1R mRNA in cases, since elevated insulin is known to down-regulate IGFBP1
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resulting in higher levels of free circulating IGF1 (9, 10) that can down-regulate IGF1R
(38). However, the association between decreased IGF1R mRNA and presence of adenomas
persisted even after adjusting for plasma insulin, suggesting that the reduced IGF1R mRNA
observed in cases was not merely a result of elevated plasma insulin in this group. We next
tested for interactions between mRNA levels and BMI or plasma insulin that may
impactcase status. We found a significant interaction between IR-A:IR-B ratio and plasma
insulin, where increased IR-A:IR-B ratio was associated with increased colorectal adenoma
risk in patients with high plasma insulin compared to those with low plasma insulin. This
suggests that circulating insulin levels may play an important role in influencing tumor risk
associated with high IR-A:IR-B expression, and that more attention should be given to the
impact of hyperinsulinemia on relative tissue expression of these IR isoforms.
Insulin has long been known to down-regulate its own receptor by negative feedback to
properly regulate glucose uptake in a number of tissues (40–44), and some evidence
suggests that hyperinsulinemia and insulin resistance can impact isoform expression (45–
48). Insulin can also down-regulate IGF1R, potentially by increasing levels of free IGF1 in
plasma (16, 37, 38). Down-regulation of IGF1R transcript in situations of high insulin has
been described in skeletal muscle of diabetic db/db mice, where reduced Igf1r mRNA
relative to normoglycemic littermates was associated with increased Igf1r promoter
methylation (49). These numerous lines of evidence for negative feedback effects of
elevated insulin are supported by the present study showing that in adenoma-free controls,
levels of IGF1R and IR mRNAs, and IR-A:IR-B ratios each negatively and significantly
correlated with plasma insulin. Qualitative analysis of IR isoforms suggested that reduced
IR-A:IR-B ratio in controls with high plasma insulin appeared to be due primarily to
increased IR-B. Patients with adenoma differed from controls in that only IGF1R mRNA
levels significantly and negatively correlated with insulin, and for IR-A:IR-B mRNA ratios
there was actually a trend for a positive correlation with insulin. This suggests a difference
in the relationship between plasma insulin and IR mRNA levels or IR-A:IR-B mRNA ratios
in cases versus controls that may be relevant to mechanisms underlying adenoma risk.
IR isoforms in humans have been studied primarily in breast and prostate cancers and it is
well established that IR-A exerts proliferative actions and is overexpressed in tumor tissue
(14, 27, 28, 50). However, little is known about the relative expression of IR isoforms in
normal gastrointestinal organs including the colorectum. Our findings that mean levels of
IR-A mRNA are about 2 fold higher than IR-B mRNA in the human rectal mucosa are
relevant to normal and aberrant growth of colon epithelium. A predominance of IR-A might
contribute to the relatively low levels of spontaneous colonocyte apoptosis (51) and
increased susceptibility to insulin-mediated reductions in apoptosis. Our recent publication
demonstrated a switch from predominance of IR-A in proliferative intestinal stem or
progenitor cells to IR-B predominance in differentiated enterocytes (31). Furthermore, IR-B
expression was reduced in mouse pre-cancerous adenomas versus normal colon and was
dramatically reduced in aggressive, poorly differentiated human CRC cell lines versus
differentiated CRC cells (31). Consistent with this finding, other studies have recently
shown that the relative mRNA levels of IR-A versus IR-B are elevated in both tumor and
grossly normal adjacent tissue of human breast and prostate, compared to purely benign
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tissue (52, 53). However, whether IR isoform expression is altered in normal colorectum in
the presence or absence of pre-malignant lesions had not to our knowledge been investigated
previously. Our study suggests that among patients in the upper half of plasma insulin, those
with adenomas had higher mean IR-A:IR-B ratio in their normal rectal mucosa compared to
controls, which appeared to result from decreased IR-B and maintained IR-A as observed by
qualitative examination. These data were supported by logistic regression analyses, which
showed that increasing IR-A:IR-B ratios predicted adenomas in patients with elevated
plasma insulin. A limitation of these findings is that they resulted from a subgroup
comparison, in a relatively small number of patients. However, they do suggest that the
relationship between plasma insulin and relative IR-A:IR-B expression in normal tissues
should be further explored, as they may be relevant to improved understanding of the roles
of hyperinsulinemia and impact of IR isoforms on colorectal tumorigenesis.
A limitation of this study is that alterations in receptor mRNA levels do not necessarily
reflect changes in protein expression and phosphorylation, as increased activation of IGF1R
and IR has been reported in cancer (54, 55). This is particularly difficult to address for IR-A
due to the lack of available antibodies to permit immunohistochemistry or western
immunoblot for this isoform. We chose to analyze RNA because sufficient RNA for
evaluation of receptor levels is readily obtained from biopsies but we recognize the
limitation with regard to predicting protein expression or activation. Another limitation of
our study is the lack of access to actual adenomas as these are considered clinical specimens
and were not available to us for research. Recent findings from our group using pre-clinical
adenoma models provided evidence for increased IR-A:IR-B ratios in colon adenomas
relative to normal colon mucosa in mice (31), but whether this is altered in humans and in
the context of elevated plasma insulin needs further investigation. An additional limitation is
that the differences in mean receptor mRNA expression across patient groups in this study
are relatively small. Despite these limitations, the potential significance of our observations
is highlighted by the growing interest in the role of the insulin/IGF pathway in cancer and
IR/IGF1R inhibitors as potential therapies (22, 24, 26). To date, IR and IR isoforms have
been understudied in the gastrointestinal tract, and our work suggests that further studies
focusing on these receptors and relative IR-A and IR-B expression are needed to better
understand their roles in initiation and pathophysiology of colorectal pre-cancerous lesions.
Therefore, our previous and current work indicates that additional attention to the relative
expression levels and biological roles of IR-A and IR-B is warranted.
Overall, this is to our knowledge the first study to show that the presence of colorectal
adenomas is associated with decreased IGF1R mRNA and, during elevated plasma insulin,
increased IR-A:IR-B mRNA ratio in normal rectal mucosa. Particularly, our data raise the
important possibility that high IR-A:IR-B mRNA ratio may contribute to colorectal
adenoma initiation during elevated plasma insulin. In addition, reduced IGF1R expression
and increased relative expression of IR-A:IR-B in normal mucosa should be further
investigated as potential predictive biomarkers of pre-malignant colorectal lesions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Representative gels showing IR-A and IR-B mRNAs in cases and controls with low and
high plasma insulin. Controls with high insulin have decreased IR-A:IR-B ratios compared
to controls with low insulin, potentially due to increased IR-B and maintained IR-A. Among
patients with high insulin, cases have higher IR-A:IR-B ratios than controls, and this appears
to result from decreased IR-B and unaltered IR-A. Samples were run in groups of 19 per gel,
and representative images were obtained from different originals or multiple fields from the
same image.
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Table 1
Descriptive characteristics of study participants
Variable Control Case P*
Age (mean (se)) 55.4 (0.7) 55.5 (0.7) 0.92
Race (n (%))
    White 76 (92) 79 (84) 0.17
    Black 7 (8) 15 (16)
Sex (n (%))
    Female 41 (48) 43 (45) 0.66
    Male 44 (52) 53 (55)
BMI (n (%))
    Normal 45 (48) 49 (49) 0.98
    Overweight 29 (31) 29 (29)
    Obese 20 (21) 21 (21)
Physical Activity in MET-minutes
per week (mean (se))
2,981 (341) 2,485 (263) 0.25
Apoptosis (mean (se)) 1.42 (0.12) 1.08 (0.06) 0.008†
Plasma insulin (mean (se)) 7.1 (0.8) 10.8 (1.7) 0.055
Calories (mean (se)) 2,101 (88) 1,949 (79) 0.20
Waist / Hip ratio (mean (se)) 0.908 (0.01) 0.915 (0.01) 0.54
*
Chi square for age, race and gender and student’s t-test for remaining variables
†
Significant at p < 0.05
MET: metabolic equivalent of task
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Table 3
ORs and 95% CIs for the association between colorectal adenomas and IGF1R, IR and IR-A:IR-B mRNA
expression
Variable n (Control/Case) OR* (95% CI) P*
IGF1R
    Q1 25/46 1.0 (Reference) -
    Q2 25/23 0.5 (0.2–1.1) 0.07
    Q3 25/19 0.4 (0.2–0.9) 0.02†
    Q4 23/12 0.3 (0.1–0.7) 0.004†
IR
    Q1 25/26 1.0 (Reference) -
    Q2 24/28 1.1 (0.5–2.4) 0.77
    Q3 25/30 1.2 (0.5–2.5) 0.71
    Q4 24/16 0.6 (0.3–1.5) 0.30
IR-A:IR-B
    Q1 25/29 1.0 (Reference) -
    Q2 24/20 0.7 (0.3–1.6) 0.42
    Q3 25/23 0.8 (0.4–1.7) 0.56
    Q4 24/28 1.0 (0.5–2.2) 0.99
*
Odds of being a case
†
Significant at p < 0.05
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Table 4
Association between colorectal adenomas and IGF1R, IR and IR-A:IR-B mRNA expression influenced by










Significant at p < 0.05
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Table 5
Correlation between plasma insulin and IGF1R, IR and IR-A:IR-B mRNA expression
Plasma insulin
Variable
Controls (n=95) Cases (n=79)
r* P r* P
IGF1R −0.21 0.045† −0.30 0.01†
IR −0.26 0.01† −0.14 0.21




Significant at p < 0.05
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